AzTrials
AzTrials

Type1diabetesNCT04384471

Covid-19 Pandemic: Patients' Experience in T1D

An observational study of Type1diabetes and Covid19, run by McGill University at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Given the current situation with COVID-19 declared pandemic on March 11, 2020 and the requirement for physical distancing and to limit social interactions, and for some, to quarantine, the investigators will survey patients living with type 1 diabetes (and their families, if they are <18 years) about their current… Read more about this study

Who is it for?
Ages 1 year and older
Conditions the study is for
Type1diabetes, Covid19
What is being tested?
Online survey
How many people
384 participants
Where
1 siteCanada
Study dates
29 Apr 2020to 1 Jul 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: -People living with type 1 diabetes in Quebec and are registered to the BETTER registry.

Who may be able to join

  • Having type 1 diabetes
  • Living in Quebec
  • Having took part in the BETTER registry (www.type1better.com)

Who cannot join

  • -Not understanding French or English

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Institut de Recherches Cliniques de Montréal

    Montreal, Quebec, H2W 1R7

Other trials in Canada

About this study

Official title: Patient Living With Type 1 Diabetes' Experience During the COVID-19 Pandemic in Quebec

Given the current situation with COVID-19 declared pandemic on March 11, 2020 and the requirement for physical distancing and to limit social interactions, and for some, to quarantine, the investigators will survey patients living with type 1 diabetes (and their families, if they are <18 years) about their current experience with their diabetes management to understand their needs.

The primary objective is to describe the exposition and the impact of COVID-19 pandemic on type 1 diabetes. The investigators will recruit people with type 1 diabetes from all ages living in Quebec to answer a short online survey.

Read the detailed description

Recruitment of people with type 1 diabetes will be done via an email sent to the participants in the BETTER registry who agreed to be contacted for other studies.

Participants of 18 years old and more will be invited to answer to the questionnaire (adult version of the questionnaires).

If the person with diabetes is aged < 18 years old, their parents will be invited to answer with them the survey ("parent" version of the questionnaire):

  • Parents from the registry (PWT1D less than 14 y.o.) will receive the invitation email
  • Participants of 14 to 18 years old who self-registered to the BETTER registry will receive an invitation email. They will be invited to complete the questionnaire with their parents. They will only have access to the "parent" version of questionnaire.

Advertising may be done through publicity on BETTER's social media (ie., Facebook, Instagram), via the BETTER monthly newsletter to increase awareness toward this research project. However the link to start the study will only be available in the email sent to the registry participants.

If people with type 1 diabetes not registered in BETTER want to participate in the present study, they will be instructed to self-register first to the registry and they will then receive a specific email to participate in the current study.

Data collection:

This will be a short online survey completed through an electronic software platform from Research Electronic Data Capture (REDCap) clinical software (English or French). The first question of the survey will be the consent form. Participants will be invited to answer the other questions only after having read the consent form and selecting 'Agree'. The consent form will also be available as a PDF document for download. The investigators have used this method in the past for the BETTER registry study. Participants will then confirm their eligibility.

The survey will include questions on acute complication (severe hypoglycemia and diabetic ketoacidosis); hypoglycemia frequency; hyperglycemia; ability to get diabetes supplies and to access diabetes care; impact of the pandemic situation on daily life activities (e.g., food insecurity, physical activity); impact on stress, anxiety and depression. The investigators will use the PHQ-9 scale for depression screening and the GAD7 scale for generalized anxiety among adult participants. The investigators will use the Short Mood and Feelings Questionnaire (SMFQ) for child and adolescent. The version used is the own that has been adapted to be completed by parents . The SMFQ was developed for use in epidemiological studies of depression in children and adolescents.

If participants show a certain level of distress, as reflected by the PHQ9 questionnaire score (≥ 10) or the SMFQ score (≥ 8), they will receive an automated email with resources that they can contact.

For PWT1D, socio-demographic information (e.g., age, ethnicity and education) and diabetes history (e.g., diabetes duration, complications) will be retrieved from the BETTER registry. Data from the registry and from this specific questionnaire will be linked using 3 identification information: the email address, the date of birth and the sex. The investigators have used this methodology for the SUPPORT study.

Analysis: The investigators will use demographic information already available on the BETTER registry. This will be a descriptive analysis. Continuous data will be reported as means with standard deviations (median and interquartile range if data are skewed). Categorical data will be reported as proportions. The investigators will do regression analysis to explore the effect of the COVID-19 pandemic duration on the patients' experience.

Thematic analysis will be performed for the free text. Content will be coded and concepts will be categorized into different themes by two researchers.

Sample size:

Based on an estimated number of 70 000 PWT1D in Quebec, a sample size of 384 completed questionnaire was calculated with an error margin of 5%, a confidence interval of 95% and a distribution of answers of 50%, A 50% distribution was used because it is impossible to predict answers; this proportion corresponds to the scenario with the larger sample size needed. Sample size was calculated using Raosoft.

Importance of this study: This study will inform about the major issues experienced by patients living with diabetes. The anxiety and added stress may lead to dysregulated blood sugars and deteriorations in their physical and mental well-being. Accesses to health care services are limited. This study will inform on the support needed by patients with type 1 diabetes during this pandemic to avoid or limit negative consequences. This may help to advocate for more remotely accessible resources for patients.

Being tested
Online survey
Keywords
Patient reported outcomes, Type1diabetes, Covid19
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Online surveyOther

    Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis

Study groups in NCT04384471
Study groupRoleWhat they receive
People living with Type 1 DiabetesPeople from all ages living with type 1 diabetes in the Province of Quebec
Receives: Other: Online survey

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Self-reported acute diabetes complication

    Severe hypoglycemia and diabetic ketoacidosis

    Measured: Since March 11, 2020

Secondary outcomes (6)
  1. Self-reported hypoglycemia

    In the last week, how many episodes of hypoglycemia did you have? Answer based on the following definition of hypoglycemia: measured blood sugar levels lower than 4.0 mmol/L and/or common symptoms [shaking, sweating, anxiety, confusion, difficulty concentrating, nausea, or other symptoms] and/or disappearance of symptoms with carbohydrate intake.

    Measured: Last 7 days

  2. Ability to get diabetes supplies and to access diabetes care

    Since the start of the COVID-19 pandemic (March 11), have you had difficulty getting a hold of any of the following diabetes supplies Scale: 1- no difficulties at all to 7- I could not get any supplies i) Blood glucose meter ii) Blood glucose meter strips iii) Insulin iv) Glucagon v) Ketone strips vi) Continuous glucose monitor sensors or related supplies vii) Insulin pump supplies viii) Alcohol wipes

    Measured: Since March 11, 2020

  3. Concern about not having access to diabetes supplies and to access diabetes care

    Since the start of the COVID-19 pandemic (March 11), are you worried about access to any of the following diabetes supplies? Scale: 1- not at all worried to 7- I am very worried i) Blood glucose meter ii) Blood glucose meter strips iii) Insulin iv) Glucagon v) Ketone strips vi) Continuous glucose monitor sensors or related supplies vii) Insulin pump supplies viii) Alcohol wipes

    Measured: Since March 11, 2020

  4. Impact of the pandemic situation on daily life activities

    Two questions on food security

    One question on physical activity

    Measured: Since March 11, 2020

  5. Impact on stress, anxiety and depression for adults participants

    PHQ-9 scale for depression screening and the GAD7 scale for generalized anxiety among adult participants.

    Measured: Last 2 weeks

  6. Impact on stress, anxiety and depression for children and adolescents

    Short Mood and Feelings Questionnaire (SMFQ) for children and adolescent.

    Measured: Last 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2020
  2. Study start29 Apr 2020
  3. Primary completion1 Jul 2020
  4. Study completion1 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
384 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04384471
Sponsor's protocol ID
2021-1079
Status last verified
Feb 2021
First submitted
1 May 2020
Last updated
24 Feb 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Type1diabetes and Covid19, run by McGill University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Self-reported acute diabetes complication (time frame: Since March 11, 2020). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in